Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

Phase

Condition

Cystic Fibrosis

Scar Tissue

Pulmonary Fibrosis

Treatment

N/A

Clinical Study ID

NCT00600028

CG-0747

Ages > 50
All Genders

Study Summary

Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough. The etiology of the cough associated with IPF is unclear but it is often so severe that it adversely effects the patient's quality of life. We propose that thalidomide specifically suppresses the cough associated with idiopathic pulmonary fibrosis via its anti-inflammatory properties, by suppressing the excessive functional up-regulation of sensory fibers with in the respiratory tract of patients with IPF.

This study is a Phase III, double blinded, randomized, placebo controlled, crossover trial testing the efficacy of thalidomide in suppressing the chronic cough of IPF. The primary objective of this study is to determine the efficacy of thalidomide administered daily for 12 weeks to suppress the chronic cough in patients with idiopathic pulmonary fibrosis as measured by cough specific questionnaires, scales and improved quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Idiopathic pulmonary fibrosis for >3 months <5 years
High resolution CT scan of chest consistent with IPF within the previous 12 months
FVC > 40% and < 90% predicted, TLC >40% <80%, DLCo >30% <90%
Chronic Cough - cough >8 weeks
Age >50
Non-child bearing potential

Exclusion

Exclusion Criteria:

Pregnant or lactating women
Women of child bearing potential
Known etiology of lung fibrosis other than IPF
Significant respiratory toxin exposure
Collagen Vascular Disease
Use of narcotic anti-cough agent in last week
significant peripheral vascular disease or neuropathy
history of seizures
poorly controlled diabetes
allergy to thalidomide

Study Design

December 01, 2007

September 30, 2011

Study Description

This study is a Phase III, double blinded, randomized, placebo controlled, crossover trial testing the efficacy of thalidomide in suppressing the chronic cough of IPF. All subjects will be randomized to either begin the study receiving the active study drug - (thalidomide) or inactive drug (placebo). Study drug will be administered in escalating dose starting at 50 mg a day increasing to 100 mg a day if cough is still present after 2 weeks. Study drug will be taken by mouth at bedtime. Patients will remain on their initial treatment for 12 weeks. After 12 weeks of treatment, the subjects will be administered the Cough Specific Quality of Life Questionnaire (CQLQ), a visual cough analogue scale, and St. Georges Respiratory Questionnaire (SGRQ). In addition, investigators will collect the subjects cough diary. After 12 weeks of treatment all subjects will enter a 2 week wash-out phase in which all drugs will be discontinued. After the 2 week wash-out phase, all subjects will again be administered the Cough Specific Quality of Life Questionnaire (CQLQ), a visual cough analogue scale, and St. Georges Respiratory Questionnaire (SGRQ). In addition, investigators will collect the subjects cough diary. All subjects will then be crossed over to the other treatment arm for an additional 12 weeks of treatment. After the second 12 weeks of treatment, the subjects will be administered the Cough Specific Quality of Life Questionnaire (CQLQ), a visual cough analogue scale, and St. Georges Respiratory Questionnaire (SGRQ). In addition, investigators will collect the subjects cough diary.

Connect with a study center

Johns Hopkins Bayview Medical Center
Baltimore, Maryland 21224
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.